Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of treatment response to mineralocorticoid receptor antagonists in primary aldosteronism: insights from the SPAIN-ALDO registry.

Journal of hypertension·2026
Same author

Acromegaly and Cardiovascular Disease: Mechanisms, Clinical Impact, and Evolving Management.

Endocrine reviews·2026
Same author

Growth hormone and glycemic metabolism.

Vitamins and hormones·2026
Same author

Clinical manifestations of primary aldosteronism and cardiometabolic risk.

Vitamins and hormones·2026
Same author

Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study.

The lancet. Diabetes & endocrinology·2026
Same author

Efficacy and safety of osilodrostat in patients with ectopic Cushing´s syndrome. a real-world study in Spain.

Journal of endocrinological investigation·2025

Related Experiment Video

Updated: May 9, 2026

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Management of subclinical hyperthyroidism.

Silvia Santos Palacios1, Eider Pascual-Corrales, Juan Carlos Galofre

  • 1Department of Endocrinology and Nutrition, University Clinic of Navarra, University of Navarra, Pamplona, Spain.

International Journal of Endocrinology and Metabolism
|July 12, 2013
PubMed
Summary
This summary is machine-generated.

Subclinical hyperthyroidism management requires careful monitoring and a 6-step approach. Treatment is essential for older adults and those with comorbidities like osteoporosis or atrial fibrillation.

Keywords:
Disease ManagementGraves’ DiseaseHyperthyroidismTherapeutics

More Related Videos

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
07:45

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

Related Experiment Videos

Last Updated: May 9, 2026

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
07:45

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

Area of Science:

  • Endocrinology
  • Internal Medicine

Background:

  • Subclinical hyperthyroidism, characterized by low thyroid-stimulating hormone (TSH) and normal thyroid hormones, presents diagnostic and management challenges.
  • Prevalence varies, notably higher in the elderly, necessitating careful evaluation to rule out transient causes or other conditions.

Purpose of the Study:

  • To outline an optimal 6-step strategy for the assessment and management of subclinical hyperthyroidism.
  • To guide endocrinologists in differentiating causes and determining treatment necessity.

Main Methods:

  • A systematic 6-step process: confirmation, severity evaluation, etiological investigation, complication assessment, treatment necessity evaluation, and treatment selection.
  • Differential diagnosis includes ruling out pituitary/hypothalamic disease, euthyroid sick syndrome, drug effects, and pregnancy.

Main Results:

  • Endogenous thyroid hormone excess, often from Graves' disease or nodular goiter, is a common cause after excluding other factors.
  • Treatment is indicated for patients over 65 or those with comorbidities such as osteoporosis and atrial fibrillation.

Conclusions:

  • Effective management of subclinical hyperthyroidism relies on vigilant monitoring of thyroid function and a structured diagnostic and treatment pathway.
  • Timely intervention is crucial for at-risk populations to prevent potential complications.